Want to track APLS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Apellis Pharmaceuticals Inc. (APLS) Statistics
Valuation metrics
Market Cap 5.25B
Enterprise value 5.32B
Trailing P/E (ttm) 38.8
Forward P/E -167.62
PEG ratio 0.07
Price/Sales (ttm) 4.75
Price/Book (mrq) 12.46
Enterprise Value/Revenue 4.81
Enterprise Value/EBITDA 29.54
Overview
Shares outstanding 126.62M
Float 83.3M
Shares short 25.12M
% Held by insiders 0.14%
% Held by institutions 0.91%
Average volume (10 days) 5.09M
Average volume (90 days) 5.8M
Price summary
52-Week low 16.61
52-Week high 41.14
Beta -0.2
50-Day moving average 23.06
200-Day moving average 24.74
Financials
Fiscal year
Fiscal year ends 31 Dec 2025
Most recent quarter (mrq) 31 Dec 2025
Profitability
Profit margin 0.12%
Operating margin 0.15%
Operational effectiveness
Return on assets 0.12%
Return on equity 0.4%
Income Statement
Revenue (ttm) 1B
Revenue per share (ttm) 8.77
Quarterly revenue growth (yoy) -0.06%
Gross profit (ttm) 605.69M
EBITDA 70M
Net income to common (ttm) 22.39M
Diluted EPS (ttm) 1.06
Quarterly earnings growth (yoy) -0.06%
Balance Sheet
Total cash (mrq) 467.79M
Total cash per share (mrq) 3.23
Total debt (mrq) 474.36M
Total Debt/Equity (mrq) 1.15
Current ratio (mrq) 3.63%
Book value per share (mrq) 3.29
Cash Flow
Cash flow statement 45.33M
Levered free cash flow (LFCF) -15.46M
